Progression-free survival (PFS) and toxicities of palbociclib in a geriatric population

K. Clifton, Yi Min, J. Kimmel, J. Litton, D. Tripathy, M. Karuturi

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Purpose: Over 40% of newly diagnosed metastatic breast cancer patients are ≥ 70 years old; however, this population is less likely to be represented in clinical trials. The objective of this study was to analyze PFS, dose reductions, dose delays, and toxicity in a geriatric population receiving palbociclib in a non-trial setting. Methods: Patients with metastatic breast cancer receiving palbociclib in any line of therapy were identified from a cohort of 845 patients at a large academic institution. Dose delays, dose reductions, and toxicities were retrospectively extracted from the medical record. Data were analyzed using Fischer’s exact test for categorized variables and T test/Wilcoxon rank-sum test for continuous variables. PFS and OS were analyzed using the Kaplan–Meier method. Results: 605 patients who met eligibility criteria were included. 160 patients were ≥ 65 years old and 92 patients were ≥ 70 years old. Patients ≥ 70 had a significantly increased number of dose reductions (p = 0.03) and dose delays (p = 0.02) compared to the younger patients. There was no significant increase in toxicities, including neutropenic fever, infections, or hospitalizations, in the ≥ 70 cohort (p = 0.3). The ≥ 70 cohort had a significantly improved PFS as compared to the younger cohort (p = 0.02); however, age was no longer a significant variable in the multivariate analysis. Conclusions: Palbociclib was well tolerated in the geriatric population and there was no difference in PFS between older and younger patients. These results are reassuring as palbociclib becomes the frontline standard of care therapy for patients.

Original languageEnglish
Pages (from-to)667-674
Number of pages8
JournalBreast Cancer Research and Treatment
Issue number3
StatePublished - Jun 30 2019


  • CDK 4/6 inhibitors
  • Hormone receptor-positive breast cancer
  • Metastatic breast cancer
  • Treatment toxicity


Dive into the research topics of 'Progression-free survival (PFS) and toxicities of palbociclib in a geriatric population'. Together they form a unique fingerprint.

Cite this